Vaishali Pharma's Q4 FY 2025-26 Quarterly Results

Result Summary

• Vaishali Pharma Ltd reported a 10.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were up by 18.0% QoQ and - - YoY.
• The net profit decreased 71.2% QoQ and - - YoY.
• The earnings per share (EPS) of Vaishali Pharma Ltd stood at 0.03 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Vaishali Pharma Ltd operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is known for providing a variety of healthcare solutions, including medicines and healthcare products. As of the latest available information, the company has not reported any major developments or changes in its business operations. The company is committed to expanding its market presence and enhancing its product offerings to meet the growing demands of the healthcare sector.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Vaishali Pharma Ltd reported a total income of ₹28.19 crores. This represents a quarter-over-quarter (QoQ) increase of 10.4% from ₹25.54 crores in the third quarter of the fiscal year 2026 (Q3FY26). The revenue data for the fourth quarter of the fiscal year 2025 (Q4FY25) is not available, thus a year-over-year (YoY) comparison cannot be made. The increase in total income from Q3FY26 to Q4FY26 reflects changes in the company's revenue streams during this period.

Profitability

For Q4FY26, Vaishali Pharma Ltd recorded a profit before tax of ₹0.18 crores, which shows a sharp decrease of 90.1% from ₹1.82 crores in Q3FY26. The tax for Q4FY26 was reported as -₹0.09 crores, a significant change from ₹0.51 crores in Q3FY26, marking a 117.6% decrease. The profit after tax for Q4FY26 was ₹0.38 crores, a decline of 71.2% compared to ₹1.32 crores in Q3FY26. The earnings per share (EPS) for Q4FY26 was ₹0.03, down from ₹0.10 in Q3FY26, indicating a decrease of 70.0%. These metrics illustrate the changes in the company's profitability over the quarter.

Operating Metrics

Vaishali Pharma Ltd's total expenses in Q4FY26 were ₹28.01 crores, marking an 18.0% increase from ₹23.73 crores in Q3FY26. This rise in expenses alongside the revenue growth indicates operational adjustments within the quarter. The financial data for the previous year (Q4FY25) is not available, which limits the ability to perform a year-over-year analysis. The provided financial data focuses on quarterly changes, highlighting the dynamics of the company's operational performance within the reported periods.